Arcus Biosciences Inc (RCUS) is a Healthcare · Biotechnology company listed on NYSE. Price $25.30 (-0.94%), Market cap $2.99B, 52-week low–high $7.95 ~ $26.62.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1
Financial statements, price targets, institutional (13F) holdings and related news for Arcus Biosciences Inc are updated in real time on BlackAll Trade.
Arcus Biosciences Inc trades at $25.30 (-0.94%). Real-time quotes and charts are available on BlackAll Trade.
Arcus Biosciences Inc has a market cap of about $2.99B.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan,